CLINICAL_TRIALS
trial_result
· 2014-09-08
Clinical Trial Update: A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes [Phase 2]
Summary
Phase II results for intravenous azacitidine used as a single agent in patients with myelodysplastic syndromes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Washington University School of Medicine | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2014-09-08